Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

Healthcare
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSXV:XRTX)

XORTX Sponsored Study Presented at the American Society of Nephrology - Kidney Week 2024

GlobeNewswire October 24, 2024

XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

GlobeNewswire October 18, 2024

XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

GlobeNewswire October 17, 2024

XORTX Initiates Precision Medicine Program

GlobeNewswire October 9, 2024

XORTX Announces Results of Annual and Special Meeting of Shareholders

GlobeNewswire September 13, 2024

XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A

GlobeNewswire September 12, 2024

XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders

GlobeNewswire September 6, 2024

Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

GlobeNewswire September 3, 2024

XORTX Highlights Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism

GlobeNewswire August 29, 2024
View More News ››

Opinion & Analysis (TSXV:XRTX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSXV:XRTX)

V.XRTX XORTX Initiates Precision Medicine Program

Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine...
Stockwonder - October 9, 2024

Independent Proxy Advisory Firm ISS Recommends XORTX Shareho

Breaking News: $XRTX Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming...
whytestocks - September 3, 2024

XRTX.v Unveils 2023 Milestones and 2024 Objectives

Yesterday, the pharmaceutical company XORTX Therapeutics Inc. (XRTX.v XRTX) shared its progress in 2023 and goals for 2024, mainly...
StockHawk1 - March 20, 2024

XORTX Highlights Achievements of 2023

CALGARY, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV...
Betteryear2 - March 19, 2024

use Bluestar BioAdvisors est. net sales to calc a CF NPV

XRx-008 Program Highlights – Independent Commercial Assessment In support of ongoing pharmaceutical partnership discussions, XORTX...
KOkidneydisease - March 19, 2024

New Patent for Treatment of Chronic Kidney Disease Submitted

Xorlo program which is in a Phase 2/3 trial in patients with stage 2-4 ADPKD.   XRTX is continuing to scale up...
waves1 - March 15, 2024
View more Bullboard ››

Fineqia International Inc.

Fineqia International Inc.

Fineqia International Inc. is a digital asset business that builds and targets investments in early and growth stage ...
View More »